Fundz

Fundz Deep Dive

Everything you need to win Biokin — in one platform.

Who to reach, what to say, and why now on Biokin — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Biokin — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Biokin Secures $250 Million Milestone Payment Through Partnership with BMS.

Oct 22, 2025•8 months ago

Contract Type

partnership

BeijingBiotechnologyHealth CarePharmaceutical

Description

In October 2025, Biokin and BMS's partnership triggered a $250 million milestone payment, marking it as a significant event in the pharmaceutical industry. The collaboration is a testament to Biokin's innovative potential and follows a record-setting $800 million upfront payment received earlier in 2024. This milestone is part of a trend of substantial out-licensing deals involving Chinese drugs.

Company Information

Company

Biokin

Location

Beijing, China

About

Biokin is a rising star in China's innovative pharmaceutical sector, specializing in novel drug development. The company is positioned as a leader in the dynamic ecosystem of biopharmaceuticals in China. With a focus on antibody-drug conjugates, Biokin aims to make significant contributions to cancer treatment. The company has recently engaged in a notable partnership with BMS.

Predictive Intelligence
Strategic

ML-powered predictions for Biokin's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.